Mineralocorticoid Receptor Blockers and Chronic Kidney Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Levey, 2005, Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, 67, 2089, 10.1111/j.1523-1755.2005.00365.x
Gansevoort, 2009, The case for using albuminuria in staging chronic kidney disease, J Am Soc Nephrol, 20, 465, 10.1681/ASN.2008111212
Hallan, 2009, Combining GFR and albuminuria to classify CKD improves prediction of ESRD, J Am Soc Nephrol, 20, 1069, 10.1681/ASN.2008070730
Eijkelkamp, 2007, Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, J Am Soc Nephrol, 18, 1540, 10.1681/ASN.2006050445
Kent, 2007, Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease, J Am Soc Nephrol, 18, 1959, 10.1681/ASN.2006101081
Bomback, 2007, The incidence and implications of aldosterone breakthrough, Nat Clin Pract Nephrol, 3, 486, 10.1038/ncpneph0575
Wenzel, 2008, Aldosterone and progression of renal disease, Curr Opin Nephrol Hypertens, 17, 44, 10.1097/MNH.0b013e3282f29028
Yoneda, 2007, Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus, Am J Hypertens, 20, 1329, 10.1016/j.amjhyper.2007.09.001
Bomback, 2008, Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review, Am J Kidney Dis, 51, 199, 10.1053/j.ajkd.2007.10.040
Navaneethan, 2009, Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis, Clin J Am Soc Nephrol, 4, 542, 10.2215/CJN.04750908
Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001
Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207
Ezekowitz, 2009, Aldosterone blockade and left ventricular dysfunction: A systematic review of randomized clinical trials, Eur Heart J, 30, 469, 10.1093/eurheartj/ehn543
Lemarie, 2008, New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone, J Mol Med, 86, 673, 10.1007/s00109-008-0323-5
Fiebeler, 2007, Aldosterone, mineralocorticoid receptors, and vascular inflammation, Curr Opin Nephrol Hypertens, 16, 134
Grossmann, 2009, New aspects of rapid aldosterone signaling, Mol Cell Endocrinol, 308, 53, 10.1016/j.mce.2009.02.005
Montezano, 2008, Networking between systemic angiotensin II and cardiac mineralocorticoid receptors, Hypertension, 52, 1016, 10.1161/HYPERTENSIONAHA.108.121269
Montezano, 2008, Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways, Arterioscler Thromb Vasc Biol, 28, 1511, 10.1161/ATVBAHA.108.168021
Zhang, 2008, Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling, Hypertension, 52, 1060, 10.1161/HYPERTENSIONAHA.108.117531
Young, 2008, Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation, Curr Opin Nephrol Hypertens, 17, 174, 10.1097/MNH.0b013e3282f56854
Stas, 2007, Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling, Endocrinology, 148, 3773, 10.1210/en.2006-1691
Yamada, 2008, Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: Possible role of AT1 receptor dimerization, Cardiovasc Res, 79, 169, 10.1093/cvr/cvn064
Thomas, 2008, Aldosterone-induced signalling and cation transport in the distal nephron, Steroids, 73, 979, 10.1016/j.steroids.2008.01.013
Wei, 2009, Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation, Hypertension, 53, 158, 10.1161/HYPERTENSIONAHA.108.121954
Shibata, 2008, Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease, Nat Med, 14, 1370, 10.1038/nm.1879
Kiyomoto, 2008, Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury, J Pharmacol Sci, 108, 399, 10.1254/jphs.08R02CR
Ritz, 2009, Role of sodium intake in the progression of chronic kidney disease, J Ren Nutr, 19, 61, 10.1053/j.jrn.2008.10.007
Ying, 1998, Dietary salt modulates renal production of transforming growth factor-beta in rats, Am J Physiol, 274, F635
Nowaczynski, 1985, Serum aldosterone and protein-binding variables in Yanomama Indians: A no-salt culture as compared to partially acculturated Guaymi Indians, Clin Physiol Biochem, 3, 289
Oliver, 1975, Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a “no-salt” culture, Circulation, 52, 146, 10.1161/01.CIR.52.1.146
Wang, 2004, Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet, Am J Physiol Renal Physiol, 286, F1178, 10.1152/ajprenal.00386.2003
Titze, 2009, Salt and its effect on blood pressure and target organ damage: New pieces in an old puzzle, J Nephrol, 22, 177
Brown, 2008, Aldosterone and vascular inflammation, Hypertension, 51, 161, 10.1161/HYPERTENSIONAHA.107.095489
Gekle, 2009, Actions of aldosterone in the cardiovascular system: The good, the bad, and the ugly?, Pflugers Arch, 458, 231, 10.1007/s00424-008-0616-0
Hunt, 2005, ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society, Circulation, 112, e154
Benson, 2004, Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity, Hypertension, 43, 993, 10.1161/01.HYP.0000123072.34629.57
Agarwal, 2008, Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease, Am J Nephrol, 28, 569, 10.1159/000115291
Keith, 2004, Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization, Arch Intern Med, 164, 659, 10.1001/archinte.164.6.659
O'Hare, 2007, Age affects outcomes in chronic kidney disease, J Am Soc Nephrol, 18, 2758, 10.1681/ASN.2007040422
Rossing, 2005, Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study, Diabetes Care, 28, 2106, 10.2337/diacare.28.9.2106
Athyros, 2007, Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: Is oral renin inhibition the solution?, Expert Opin Pharmacother, 8, 529, 10.1517/14656566.8.5.529
McMurray, 2008, Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure, Circ Heart Fail, 1, 17, 10.1161/CIRCHEARTFAILURE.107.740704
Oparil, 2007, Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial, The Lancet, 370, 221, 10.1016/S0140-6736(07)61124-6
Ubaid-Girioli, 2009, Aldosterone excess or escape: Treating resistant hypertension, J Clin Hypertens (Greenwich, 11, 245, 10.1111/j.1751-7176.2009.00110.x
Ohtani, 2007, Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker, Am J Physiol Regul Integr Comp Physiol, 292, R946, 10.1152/ajpregu.00402.2006
Chen, 2008, Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade, Kidney Int, 74, 1128, 10.1038/ki.2008.380
Macconi, 2008, Candesartan and renal protection: More than blocking angiotensin type 1 receptor?, Kidney Int, 74, 1112, 10.1038/ki.2008.420
Ruggenenti, 2009, Proteinuria: Increased angiotensin-receptor blocking is not the first option, Nat Rev Nephrol, 5, 367, 10.1038/nrneph.2009.77
Burgess, 2009, Supramaximal dose of candesartan in proteinuric renal disease, J Am Soc Nephrol, 20, 893, 10.1681/ASN.2008040416
Pisoni, 2002, Effect of high dose ramipril with or without indomethacin on glomerular selectivity, Kidney Int, 62, 1010, 10.1046/j.1523-1755.2002.00535.x
Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2
Berns, 2009, Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD?, Am J Kidney Dis, 53, 192, 10.1053/j.ajkd.2008.11.016
Sarafidis, 2008, Renin-angiotensin blockade and kidney disease, Lancet, 372, 511, 10.1016/S0140-6736(08)61212-X
Tylicki, 2007, Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney, Kidney Int, 72, 1164, 10.1038/sj.ki.5002511
Weir, 2008, Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added trial, Eur J Heart Fail, 10, 157, 10.1016/j.ejheart.2007.12.006
Furumatsu, 2008, Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker, Hypertens Res, 31, 59, 10.1291/hypres.31.59
Tylicki, 2008, Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial, Am J Kidney Dis, 52, 486, 10.1053/j.ajkd.2008.02.297
Cravedi, 2009, Intensified inhibition of renin-angiotensin system: A way to improve renal protection?, Curr Hypertens Rep, 11, 118, 10.1007/s11906-009-0022-9
Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161
Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303
de Zeeuw, 2004, Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL, Kidney Int, 65, 2309, 10.1111/j.1523-1755.2004.00653.x
Menon, 2009, Differential effects of chlorthalidone vs. spironolactone on muscle sympathetic nerve activity in hypertensive patients, J Clin Endocrinol Metab, 94, 1361, 10.1210/jc.2008-2660
Palmer, 2004, Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system, N Engl J Med, 351, 585, 10.1056/NEJMra035279
Besancon, 2008, Study of the use of a spironolactone and angiotensin-converting enzyme inhibitor combination: A population-based analysis, Pharmacoepidemiol Drug Saf, 17, 172, 10.1002/pds.1511
Ko, 2006, Appropriateness of spironolactone prescribing in heart failure patients: A population-based study, J Card Fail, 12, 205, 10.1016/j.cardfail.2006.01.003
Gross, 2005, Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients, Am J Kidney Dis, 46, 94, 10.1053/j.ajkd.2005.03.005
Matsumoto, 2009, Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients, Cardiology, 114, 32, 10.1159/000210553
Taheri, 2009, Spironolactone in chronic hemodialysis patients improves cardiac function, Saudi J Kidney Dis Transpl, 20, 392
Preston, 2009, Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease, Hypertension, 53, 754, 10.1161/HYPERTENSIONAHA.108.125252
Pitt, 2009, The role of aldosterone blockade in end-stage renal disease, Cardiology, 114, 30, 10.1159/000210552
Einhorn, 2009, The frequency of hyperkalemia and its significance in chronic kidney disease, Arch Intern Med, 169, 1156, 10.1001/archinternmed.2009.132